Genprex Inc (GNPX): The entire BOD CEO and anyone associated... (2024)

Public Reply Private Reply New Post

Replies (1) Keep Next 10 Report Keyboard Shortcuts

The entire BOD CEO and anyone associated with these possible pyramid schemes to raise money off the thought of Cancer need jail?

Ryan M confer might need to be in prison?

Genprex CEO possibly knows exactly the type of diluted pyramid scheme it is running?

Prison could have been a better fit for Varner but who I am I to question the lords work?

IMO

Everything I post, is In my own opinion, I don't care what you think about it, if you disagree, post it like I do. If you buy or sell stock based on what I say, your a lunatic and should not be trading. Have a great day!

Replies (1) Next 10 Prev Next

• Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:18:55 PM
• Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials • PR Newswire (US) • 08/15/2024 01:30:00 PM
• Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer • PR Newswire (US) • 08/14/2024 01:25:00 PM
• Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:38:12 PM
• Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers • PR Newswire (US) • 08/13/2024 12:31:00 PM
• Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:31:26 PM
• Genprex to Present at the August Sidoti Microcap Conference • PR Newswire (US) • 08/08/2024 12:30:00 PM
• Genprex Issues Stockholder Letter and Provides 2024 Corporate Update • PR Newswire (US) • 06/27/2024 12:31:00 PM
• Genprex to Present at the 2024 BIO International Convention • PR Newswire (US) • 05/30/2024 12:31:00 PM
• Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:35:51 PM
• Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:15:54 PM
• Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 05/14/2024 12:31:00 PM
• Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors • PR Newswire (US) • 05/13/2024 12:31:00 PM
• Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:11:07 PM
• Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner • PR Newswire (US) • 05/08/2024 10:08:00 PM
• Genprex to Present and Participate at Upcoming May Investor and Industry Conferences • PR Newswire (US) • 05/01/2024 12:31:00 PM
• Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 04/09/2024 12:31:00 PM
• Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 04/03/2024 12:31:00 PM
• Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System • PR Newswire (US) • 04/02/2024 12:31:00 PM
• Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/22/2024 08:10:00 PM
• Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 05:24:00 PM
• Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 12:36:00 PM
• Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 03/12/2024 01:01:00 PM
• Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:18:38 PM
• Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 03/06/2024 01:30:00 PM

More GNPX News

InvestorsHub NewsWire

HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM

PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM

VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM

Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM

Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM

POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM

Start posting your company's news

Only $200 per official company press release!